Strategic review of the Consumer Tissue Private Label Europe business concluded

REG

Essity continuously evaluates its various businesses to increase long-term value creation. In the strategic review of Consumer Tissue Private Label Europe it was concluded that the business as a result of the implemented divisionalization, is a competitive and value-creating part of Essity. 

Net sales for the Consumer Tissue Private Label Europe business amounted to approximately SEK 9.8bn in 2022. The business encompasses seven production facilities in Belgium, France, Germany and Italy with approximately 1,900 employees. 

NB: This is information that Essity Aktiebolag (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 17:30 CET on December 14, 2023.  

Karl Stoltz, Media Relations Director, +46 709 42 63 38   

Datum 2023-12-14, kl 17:30
Källa Cision
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!